AstraZeneca Looks To Take On GSK And Merck In Endometrial Cancer With Imfinzi Nod

17 Jun 2024

The FDA has approved the UK firm's checkpoint inhibitor to treat patients whose cancer is mismatch repair deficient (dMMR). The next challenge is to have a treatment for the remaining 70-80% of endometrial cancer patients with mismatch repair proficient (pMMR) disease.

AstraZeneca PLC's PD-L1 inhibitor Imfinzi has secured approval in the US for endometrial cancer, providing competition for GSK plc's checkpoint inhibitor Jemperli and Merck & Co., Inc.'s behemoth Keytruda.

The US Food and Drug Administration has given the green light to the AstraZeneca therapy in combination with the chemotherapies...